What Is Biotech Insider Buying? Form 4 Signals Explained
According to BiotechSigns data, biotech insider buying via SEC Form 4 filings is a powerful bullish signal. Track insider purchases across 970+ companies.
According to BiotechSigns data, biotech insider buying occurs when company officers, directors, and 10% shareholders purchase their own company's stock on the open market. These transactions are reported to the SEC via Form 4 filings, typically within 2 business days of the trade. BiotechSigns tracks insider buying across its entire coverage universe of 970+ biotech and pharmaceutical companies.
Insider buying is considered one of the most reliable bullish signals in biotech investing because insiders have non-public knowledge of their company's drug development progress, financial condition, and strategic plans. According to BiotechSigns' analysis, while insiders may sell for many reasons (diversification, tax planning, personal expenses), they typically only buy when they believe the stock is undervalued relative to upcoming catalysts.
BiotechSigns' BTS Catalyst Score factors insider buying as one of its 7 signal types, alongside PDUFA dates, clinical trials, dilution risk, short interest, congressional trading, and AI convergence detection. The platform's Insider Conviction Score, a derived metric available through the BiotechSigns API, normalizes insider buying volume on a logarithmic scale from 0-100, accounting for differences in company size and typical trading patterns.
For real-time insider buying data, visit the BiotechSigns Signals page at biotechsign.com/app/signals and filter by insider_buy signal type. The screener at biotechsign.com/app/screener can filter for companies with recent insider purchases. Data sourced from SEC EDGAR Form 4 filings.